Revista espanola de medicina nuclear e imagen molecular最新文献_第5页

Prostatic rhabdomyosarcoma in a 6 years old patient evaluated by [18F]FDG PET/CT 用[18F]FDG PET/CT 评估一名 6 岁患者的前列腺横纹肌肉瘤。

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500016

引用次数: 0

US-guided percutaneous ablation of thyroid nodules with 177LU-MAA (LUTMA) - Feasibility study US-guided percutaneous ablation of thyroid nodules with 177LU-MAA (LUTMA) - Feasibility study.

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500023

{"title":"US-guided percutaneous ablation of thyroid nodules with 177LU-MAA (LUTMA) - Feasibility study","authors":"","doi":"10.1016/j.remnie.2024.500023","DOIUrl":"10.1016/j.remnie.2024.500023","url":null,"abstract":"<div><h3>Purpose</h3><p>The main purpose is to evaluate the safety, and efficacy of <sup>177</sup><span>Lutetium labeled macroaggregated albumin (LUTMA) ablation of thyroid nodules.</span></p></div><div><h3>Materials and methods</h3><p>Patients with confirmed benign nodules who were not candidate or did not accept surgery were enrolled. Under ultrasonography (USG) guidance, LUTMA which was produced in our department, was administered into the nodules. Nodule volumes were assessed via USG before the injection and at 1-week, 1-month, and 3-months post-treatment. We calculated the volume reduction rates (VRRs) for these intervals. To detect extranodular activity leakage, patients underwent SPECT/CT imaging at one hour, 24 h, and one week post-injection.</p></div><div><h3>Results</h3><p><span>Fifteen patients (male: 12, female: 3) with benign thyroid nodules were eligible to join this study. These nodules were categorized as cystic (n = 9), solid (n = 3), or mixed (n = 3). Median nodules volume was 6.59 ml (range: 0.56–55 ml). Predicted absorbed dosee to the nodules varied between 10–1036 Gy. The VRRs at 3 months was 85% for all nodule types with gradual increases over time: 0%–92%, 20%–97%, and 28%–98% at 1 week, 1 month, and 3-months, respectively. The median VRR of cystic nodules was 89% (range: 81%–98%) at 3-months. It is significantly higher than solid ones (</span><em>P</em><span> = .009). None of the patients experienced adverse reactions or discomfort during the injection or follow-up.</span></p></div><div><h3>Conclusion</h3><p>LUTMA treatment significantly reduces the volume of benign thyroid nodules, offering relief from disease-associated symptoms and cosmetic concerns. It emerges as a promising alternative to surgical and other local treatments for benign thyroid nodule ablation.</p></div><div><h3>Clinical signification</h3><p><span>LUTMA is a novel theranostic radiopharmaceutical which is promising in local </span>ablative treatment of benign thyroid nodules.</p></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141187155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging characteristics of an atypical spinal angiolipoma on PET/CT and MRI PET/CT 和 MRI 上非典型脊髓血管脂肪瘤的成像特征。

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500015

引用次数: 0

Radio theranostics in paragangliomas and pheochromocytomas 副神经节瘤和嗜铬细胞瘤的放射治疗技术。

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500017

引用次数: 0

Recurrent sinonasal meningioma: insights from somatostatin receptor imaging 复发性鼻窦脑膜瘤：体生长抑素受体成像的启示。

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500014

引用次数: 0

Update on radiation protection of the thyroid gland 甲状腺辐射防护的最新进展。

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500026

引用次数: 0

Assessment of incidental cardiac uptake in bone scintigraphy across Spain: The ECCINGO study 西班牙骨闪烁成像中偶然摄取的心脏摄取量评估--ECCINGO 研究。

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500020

{"title":"Assessment of incidental cardiac uptake in bone scintigraphy across Spain: The ECCINGO study","authors":"","doi":"10.1016/j.remnie.2024.500020","DOIUrl":"10.1016/j.remnie.2024.500020","url":null,"abstract":"<div><h3>Aim</h3><p>Myocardial uptake on bone scintigraphy has become useful for the detection of transthyretin cardiac amyloidosis (ATTR-CA). This study aimed to assess the prevalence of myocardial uptake in patients over 18 years of age with no clinical suspicion of cardiac amyloidosis (CA) who had undergone bone scintigraphy.</p></div><div><h3>Methods and results</h3><p>This was an observational, retrospective, multicenter study across 21 Spanish hospitals (September–November 2019). Of the 9864 scans analyzed (locally and centrally), incidental cardiac uptake was observed in 71 patients (0.72%), a prevalence that increased with age. A previous diagnosis of heart failure was found in 16.9% of patients with positive uptake, with >50% in NYHA II. ATTR-CA was diagnosed in 10 patients, with a mean delay of 10.4 months (95% CI: 5.1–15.7). All were >70 years old, primarily male, and had greater left ventricular hypertrophy than patients without a confirmed diagnosis (<em>p</em>  =0.025).</p></div><div><h3>Conclusions</h3><p>This is the first retrospective, national, multicenter study evaluating the prevalence of incidental cardiac uptake in bone scintigraphy performed for non-cardiac reasons, showing a prevalence of 0.72% in this population. Referral of these patients may facilitate early diagnosis of CA with a resulting benefit for patients.</p></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2253808924000363/pdfft?md5=75a7fd39af35c157e9b416aacf8f86c9&pid=1-s2.0-S2253808924000363-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141185003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk management of radioiodine treatment in differentiated thyroid cancer 分化型甲状腺癌放射性碘治疗的风险管理。

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2024-07-01 DOI: 10.1016/j.remnie.2024.500029

J. Villena-Salinas , M.A. Sempere Alcocer , M. Gallego Peinado

{"title":"Risk management of radioiodine treatment in differentiated thyroid cancer","authors":"J. Villena-Salinas , M.A. Sempere Alcocer , M. Gallego Peinado","doi":"10.1016/j.remnie.2024.500029","DOIUrl":"10.1016/j.remnie.2024.500029","url":null,"abstract":"<div><h3>Introduction</h3><p>Patient safety is paramount in providing quality healthcare and constitutes a global concern for healthcare systems. Radioiodine treatment to patients with well-differentiated thyroid cancer is not without risks. The aim of this study is to identify, evaluate and mitigate the risks associated with this procedure.</p></div><div><h3>Materials and methods</h3><p>A single-centre descriptive study was conducted in which risk management was carried out by establishing a risk map using FMEA methodology.</p></div><div><h3>Results</h3><p>Based on the process map 6 sub-processes and 23 failure modes in the three phases of the treatment process were analysed. According to risk priority number (RPN), the sub-process with the highest risk was administrative management (RPN 82), followed by treatment per se and post-treatment imaging (both with RPN 70). An overall process RPN of 300 (156 pre-treatment, 74 treatment and 70 post-treatment) was obtained. Failures directly related to the patient pose a high risk. The implementation of verification systems, performing tasks earlier and providing quality medical information are the most relevant preventive measures to be implemented.</p></div><div><h3>Conclusions</h3><p>The application of the FMEA methodology in the risk management for radioiodine treatment is a valuable tool for improving the quality and safety of this process. The risk map has been able to identify failures at different stages, assess their causes and effects, prioritise the risks identified and implement preventive and corrective measures that can be monitored, ensuring the effectiveness of the actions taken.</p></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A serial image analysis architecture with positron emission tomography using machine learning combined for the detection of lung cancer 利用机器学习结合正电子发射断层扫描的序列图像分析架构，用于检测肺癌。

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2024-05-01 DOI: 10.1016/j.remnie.2024.500003

S. Guzmán Ortiz , R. Hurtado Ortiz , A. Jara Gavilanes , R. Ávila Faican , B. Parra Zambrano

{"title":"A serial image analysis architecture with positron emission tomography using machine learning combined for the detection of lung cancer","authors":"S. Guzmán Ortiz , R. Hurtado Ortiz , A. Jara Gavilanes , R. Ávila Faican , B. Parra Zambrano","doi":"10.1016/j.remnie.2024.500003","DOIUrl":"10.1016/j.remnie.2024.500003","url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>Lung cancer is the second type of cancer with the second highest incidence rate and the first with the highest mortality rate in the world. Machine learning through the analysis of imaging tests such as positron emission tomography/computed tomography (PET/CT) has become a fundamental tool for the early and accurate detection of cancer. The objective of this study was to propose an image analysis architecture (PET/CT) ordered in phases through the application of ensemble or combined machine learning methods for the early detection of lung cancer by analyzing PET/CT images.</p></div><div><h3>Material and methods</h3><p>A retrospective observational study was conducted utilizing a public dataset entitled “A large-scale CT and PET/CT dataset for lung cancer diagnosis.” Various imaging modalities, including CT, PET, and fused PET/CT images, were employed. The architecture or framework of this study comprised the following phases: 1. Image loading or collection, 2. Image selection, 3. Image transformation, and 4. Balancing the frequency distribution of image classes. Predictive models for lung cancer detection using PET/CT images included: a) the Stacking model, which used Random Forest and Support Vector Machine (SVM) as base models and complemented them with a logistic regression model, and b) the Boosting model, which employed the <em>Adaptive Boosting</em> (<em>AdaBoost</em>) model for comparison with the Stacking model. Quality metrics used for evaluation included accuracy, precision, recall, and F1-score.</p></div><div><h3>Results</h3><p>This study showed a general performance of 94% with the Stacking method and a general performance of 77% with the Boosting method.</p></div><div><h3>Conclusions</h3><p>The Stacking method proved to be a model with high performance and quality for lung cancer detection when analyzing PET/CT images.</p></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140760115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and validation of an alternative procedure for quantitative quality control analysis of 99mTc-radiopharmaceuticals using a Geiger Müller counter 开发和验证使用盖革-缪勒计数器对 99mTc 放射性药物进行定量质量控制分析的替代程序。

Revista espanola de medicina nuclear e imagen molecular Pub Date : 2024-05-01 DOI: 10.1016/j.remnie.2024.500006

M.M. Gonzalez , A.L. Poma , N. Cuello , A.L. Soldati

{"title":"Development and validation of an alternative procedure for quantitative quality control analysis of 99mTc-radiopharmaceuticals using a Geiger Müller counter","authors":"M.M. Gonzalez , A.L. Poma , N. Cuello , A.L. Soldati","doi":"10.1016/j.remnie.2024.500006","DOIUrl":"10.1016/j.remnie.2024.500006","url":null,"abstract":"<div><h3>Background and objectives</h3><p>In a hospital radiopharmacy with 2a operational level, including the preparation of radiopharmaceuticals from prepared and approved reagent kits, it is common to have a single activimeter or dose calibrator for labeling and fractionation, and to perform the quality controls of the <sup>99m</sup>Tc-radiopharmaceuticals. In certain cases, the accumulation of radioactive material or accidental contamination of the work area causes the background to exceed the limits to carry out the radiochemical purity analyses and it is necessary to look for viable alternatives. In this work, a Geiger Müller detector (equipped with a probe for measuring surface contamination) frequently used for radioprotection purposes, was validated as an alternative and its performance was compared against the activimeter for <sup>99m</sup>Tc-radiopharmaceuticals.</p></div><div><h3>Materials and methods</h3><p>Using [<sup>99m</sup>Tc]pertechnetate, systematic studies of error analyses and detector response to activity concentration, activity and measurement time were carried out in liquid matrices and in paper. The results were compared against an activimeter calibrated for [<sup>99m</sup>Tc]Tc.</p></div><div><h3>Results</h3><p>The developed method was used to determine the radiochemical purity of the compounds [<sup>99m</sup>Tc]Tc-MDP and [<sup>99m</sup>Tc]Tc-MIBI by ascending paper chromatography tests, obtaining comparable values to those measured with an activimeter in the same system (within 1% uncertainty) and using the method of vial partitioning in a dedicated equipment.</p></div><div><h3>Conclusions</h3><p>This work demonstrates that a Geiger Müller detector with a probe for measuring surface contamination can be adequately used to replace other equipment in the control of radiochemical purity in the hospital radiopharmacy.</p></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140779895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0